Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Non Operating Income (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Non Operating Income for 13 consecutive years, with -$105.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 468.24% year-over-year to -$105.0 million, compared with a TTM value of -$105.3 million through Dec 2025, down 344.41%, and an annual FY2025 reading of -$105.3 million, down 344.41% over the prior year.
  • Non Operating Income was -$105.0 million for Q4 2025 at Karyopharm Therapeutics, down from -$17.9 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $28.5 million in Q4 2024 and bottomed at -$105.0 million in Q4 2025.
  • Average Non Operating Income over 5 years is -$3.0 million, with a median of -$142000.0 recorded in 2022.
  • The sharpest move saw Non Operating Income crashed 30322.22% in 2022, then soared 13617.54% in 2024.
  • Year by year, Non Operating Income stood at -$478000.0 in 2021, then surged by 3880.96% to $18.1 million in 2022, then plummeted by 101.17% to -$211000.0 in 2023, then skyrocketed by 13617.54% to $28.5 million in 2024, then plummeted by 468.24% to -$105.0 million in 2025.
  • Business Quant data shows Non Operating Income for KPTI at -$105.0 million in Q4 2025, -$17.9 million in Q3 2025, and -$2.2 million in Q2 2025.